Dacosta-Aguayo Rosalia, Lamonja-Vicente Noemí, Chacón Carla, Carrasco-Ribelles Lucia Amalía, Montero-Alia Pilar, Costa-Garrido Anna, García-Sierra Rosa, López-Lifante Victor M, Moreno-Gabriel Eduard, Massanella Marta, Puig Josep, Muñoz-Moreno Jose A, Mateu Lourdes, Prats Anna, Rodríguez Carmina, Mataró Maria, Prado Julia G, Martínez-Cáceres Eva, Violán Concepción, Torán-Monserrat Pere
Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), 08303 Mataró, Spain.
Comparative Medicine and Bioimaging Center (CMCiB), Germans Trias i Pujol Research Institute, 08916 Badalona, Spain.
Vaccines (Basel). 2022 May 26;10(6):849. doi: 10.3390/vaccines10060849.
The diagnosis of the post-COVID condition is usually achieved by excluding other diseases; however, cognitive changes are often found in the post-COVID disorder. Therefore, monitoring and treating the recovery from the post-COVID condition is necessary to establish biomarkers to guide the diagnosis of symptoms, including cognitive impairment. Our study employs a prospected cohort and nested case-control design with mixed methods, including statistical analyses, interviews, and focus groups. Our main aim is to identify biomarkers (functional and structural neural changes, inflammatory and immune status, vascular and vestibular signs and symptoms) easily applied in primary care to detect cognitive changes in post-COVID cases. The results will open up a new line of research to inform diagnostic and therapeutic decisions with special considerations for cognitive impairment in the post-COVID condition.
新冠后状况的诊断通常通过排除其他疾病来实现;然而,认知变化在新冠后疾病中经常被发现。因此,监测和治疗新冠后状况的恢复情况对于建立生物标志物以指导包括认知障碍在内的症状诊断是必要的。我们的研究采用前瞻性队列和嵌套病例对照设计,并结合统计分析、访谈和焦点小组等混合方法。我们的主要目标是识别易于应用于初级保健的生物标志物(神经功能和结构变化、炎症和免疫状态、血管和前庭体征及症状),以检测新冠后病例中的认知变化。研究结果将开辟一条新的研究途径,为新冠后状况下认知障碍的诊断和治疗决策提供信息,并给予特别考虑。